Background
==========

The metabolic syndrome, currently prevalent in 20% - 25% of the world\'s adult population, is a significant risk factor for cardiovascular disease, type 2 diabetes and cancer \[[@B1]\]. It consists of clinical symptoms and abnormal lab results, including abdominal obesity, insulin resistance, hyperglycemia, hyperlipidemia, and hypertension \[[@B1]\].

Ferritin, an ubiquitous intracellular protein that is key in the regulation of iron homeostasis, is an accepted biomarker to evaluate body iron stores \[[@B2]\]. However, increasing evidence indicates that elevated body iron stores may be associated with adverse health outcomes. Elevated serum ferritin levels have been demonstrated to independently predict type 2 diabetes mellitus in several meta-analyses \[[@B3]-[@B5]\]. In cross-sectional studies, elevated ferritin levels have been associated with hypertension \[[@B6]\], dyslipidemia \[[@B7],[@B8]\], elevated fasting insulin and blood glucose levels \[[@B9]\], and central adiposity \[[@B10]\]. However, no meta-analysis has specifically focused on high ferritin blood concentrations in relation to the presence of the metabolic syndrome. Moreover, the presence of inflammation has not been systematically taken into account, leading to conflicting results \[[@B11]-[@B22]\].

Evaluating if high serum ferritin is associated with the metabolic syndrome is relevant for both the clinician and the public health areas that focus on screening and prevention.

In order to address this issue we aimed in this study to meta-analyze the findings of published original research articles investigating the relationship between serum ferritin and the presence of the metabolic syndrome in adults of both genders in prospective cohort and cross-sectional studies.

Methods
=======

Search strategy
---------------

We searched PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), the SCOPUS and Cochrane Central Database for observational studies, investigating the association between serum ferritin levels and metabolic syndrome.

We used free text and the Medical Subject Heading (MeSH) terms *metabolic syndrome, iron, ferritin, transferrin, ferritins, iron stores, iron status, iron intake, iron consumption, heme iron*. The search period was all-inclusive until February 2014; no language restrictions were added. We also reviewed the reference lists of the retrieved original articles.

Study selection
---------------

We included all observational studies (cross-sectional, case--control and prospective) that were conducted in adults aged ≥ 18 years, assessing the association between serum ferritin and metabolic syndrome.

Exclusion criteria were the following: 1) no original research (reviews, editorials, non-research letters); 2) case reports and case series; 3) studies concerning children, adolescents and pregnant women; 4) study subjects with hemochromatosis, chronic liver disease, liver cirrhosis or chronic renal diseases; and 5) studies with Type 1 diabetes mellitus or Type 2 diabetes mellitus participants.

For study populations generating more than one report \[[@B20],[@B22]-[@B26]\], we selected the study with the largest number of participants \[[@B20],[@B22],[@B27]\].

Data extraction and quality assessment
--------------------------------------

Two investigators (G.F-M and V.A-U) independently reviewed the search results and selected articles to determine eligibility and to extract study data. A third investigator independently reviewed the published data (V.A). They resolved discrepancies by consensus. Extracted data included information on the study design (prospective cohort, cross-sectional and other designs), measures of association used (odds ratio or hazard ratio), country of origin, population, sex, average age of participants, number of participants, ferritin assay technique, ferritin levels, metabolic syndrome criteria and outcomes.

The investigators of the original studies were contacted if relevant information on eligibility or key study data were not available in the published report.

To assess study quality, we used the STROBE statement of observational studies \[[@B27]\]. Each of the criteria was categorized as clearly yes or clearly no. A score between 0 and 22 was assigned to allow for quality analysis (0 denoted noncompliance with any criteria, and 22 denoted fulfillment of all criteria). Our meta-analysis was registered on the website of the International prospective register of systematic reviews, PROSPERO (CRD42012002258).

Data synthesis and statistical analysis
---------------------------------------

Measures of association (odds ratio (OR), relative risks or hazard ratios) and their 95% CIs were extracted or derived by using the data reported in the publications. When several measures of association were reported, we chose the measure obtained from the model of the highest category for ferritin concentration and as second choice, the measure adjusted for most covariates. For studies that categorized ferritin levels, we compared the risk of metabolic syndrome in the highest with the lowest ferritin category. For studies reporting only mean levels of ferritin in case and non-case subjects \[[@B12],[@B14]\], we used linear discriminant function methods \[[@B28]\] to calculate the OR in a comparison of the 75th to the 25th percentiles of the ferritin distribution in non-case subjects, assuming a normal distribution for ferritin.

To pool OR estimates from individual studies, we used an inverse variance weighted random-effects model. Heterogeneity was quantified with the *I*^2^ statistic which describes the proportion of total variation in the study estimates that is due to heterogeneity \[[@B29]\]. To explore sources of heterogeneity, we performed subgroup analysis and meta-regression to evaluate whether results were different depending on the study design (prospective (cohort), cross-sectional and other designs, on the measure of association used (odds ratio or hazard ratio), geographic area (Asian, Europe or American), adjusted for C-reactive protein (CRP) (yes or not), quality of the study (\<30 points or equal or higher than 30 points of SCORE statement of 34 as maximum points), ferritin technique assay (immunoradiometric assay RIA; immunoturbidimetric assay, TIA; or others) and study size (\<300 or equal or higher than 300 participants).

We used sensitivity analyses to assess the relative influence of each study on the pooled estimates by omitting one study at a time. Finally, we assessed publication bias using funnel plots \[[@B30]\].

Our results were expressed as pooled OR.

Statistical analysis was performed using Stata software (version 11.0; Stata Corp, College Station, TX, USA).

Results
=======

Study selection
---------------

The search strategy retrieved 243 unique citations in the Pubmed, 644 in the SCOPUS and 0 in the Cochrane Library (Figure [1](#F1){ref-type="fig"}). Of these citations, 238 and 636 respectively, were excluded after screening on the basis of title and abstract and 7 after full-text review, leaving twelve cross sectional studies \[[@B11]-[@B20],[@B22],[@B31]\], one case--control study \[[@B21]\] and two prospective cohort studies \[[@B26],[@B32]\] for final inclusion in the meta-analysis. Fourteen articles were in English and one in Korean (Its abstract was in English). The fifteen studies found \[[@B11]-[@B22],[@B26],[@B31],[@B32]\] were published between 2004 and February 2014. One study was performed in the United States \[[@B11]\], nine studies in Asia \[[@B13],[@B15]-[@B18],[@B20],[@B22],[@B26],[@B31]\]; four in Europe \[[@B12],[@B14],[@B21],[@B32]\] and one in Chile \[[@B19]\]. The number of subjects per study varied between 155 \[[@B19]\] to 13,084 \[[@B26]\] (Table [1](#T1){ref-type="table"}).

![Flow diagram of the study selection process.](1471-2458-14-483-1){#F1}

###### 

Cross sectional and cohort studies on Ferritin level and of the Metabolic Syndrome

   **First author Year (Reference number)**   **Country**    **Study design**                                 **Population**                                 **Men (%)**   **Age years**   **Sample**   **Ferritin assay**    **Metabolic syndrome criteria**                     **Ferritin concentration (μg/l)**                                                **\*Quality score**                               
  ------------------------------------------ ------------- -------------------- --------------------------------------------------------------------------- ------------- --------------- ------------ -------------------- ----------------------------------- --------------------------------------------------------------------- ------------------------------------------------------------------------------ ----
            Jehn, 2004 \[[@B11]\]                U.S.        Cross-sectional                      NHANES III (1988--1994) U.S. Population                        48             48           5,949             RIA                      NCEP ATPIII                                      Q1:62^a^ Q4:318^a^                                Premenopausal: Q1:11^a^ Q4:89^a^ Postmenopausal: Q1:35^a^ Q4:212^a^        30
           Bozzini, 2005 \[[@B12]\]              Italy       Cross-sectional                               Verona Heart Project                                  73             58            479              NIA                      NCEP ATPII               Both genders: With MS: 124 (111--138)^b^ Without MS: 83 (73--94)^b^                                        19                                       
            Choi, 2005 \[[@B13]\]                Korea       Cross-sectional                       Welfare Centers of Seoul Metropolitan                          0             72            959              EIA                     NCEP original                                                                                                     With MS: 74 ± 2^c^ Without MS: 59 ± 2^c^                     28
        Soto González 2006 \[[@B14]\]            Spain       Cross-sectional          Patients of the Endocrinoloy and Nutrition Service of Hospital             34             38            598              RIA                      NCEP ATPIII              Both genders: With MS: 133.9 ± 141.1^d^ Without MS: 66.8 ± 71.8^d^                                         31                                       
            Vari, 2007 \[[@B32]\]               France      Prospective cohort                DESIR cohort French people 6 years of follow up                    49             47            944              NIA                      NCEP ATPIII                                    At baseline 178 ± 90^d^                         At baseline Premenopausal women: 56 ± 40^d^ Postmenopausal women: 92 ± 54^d^   32
             Shi, 2008 \[[@B15]\]                China       Cross-sectional                   The 2002 National Nutrition and Health survey                     46            40-49         2,816             RIS                          NR                                          Q4:257 (176--500)^e^                                                       Q4:170 (96--504)^e^                                30
             Sun, 2008 \[[@B16]\]                China       Cross-sectional                     Nutrition and Health of Aging population                        44             58           3,165             TIA                      NCEP ATPIII                           Q1:71 (68--73.2)^b^ Q4:327 (316--340)^b^                                    Q1:52 (51--54)^b^ Q4:231(224--239)^b^                       30
             Ryu, 2008 \[[@B17]\]                Korea       Cross-sectional                            Korean Rural GENOMIC Cohort                              38             58           1,444             N.R                      NCEP ATPIII                                  Q1:45 ± 2^f^ Q4:258 ± 12^f^                                                Q1:17 ± 2^f^ Q4:131 ± 1^f^                            32
             Kim, 2011 \[[@B18]\]                Korea       Cross-sectional                                Healthy volunteers                                   53             51           7,253             TIA                      NCEP ATPIII                                         176 ± 108^d^                                                                75 ± 55^d^                                    30
            Park, 2012 \[[@B26]\]                Korea      Prospective cohort                  Check-up of men in Health Promotion Center                       100            44           13,084                          International Diabetes Federation                         At baseline 112 ± 64^d^                                                  \-\-\-\-\-\-\-\-\-\-\-\--                             31
            Kang, 2012 \[[@B20]\]                Korea       Cross-sectional              South Korean general population KNANHES IV (2007--2008)                44             48           7,346             RIA                      NCEP ATPIII                             Q1:46 (33, 55)^g^ Q4:194(167, 247)^g^                                  Q1:13 \[[@B9],[@B17]\]^g^ Q4:90 (75, 114)^g^                   27
         Hämäläinen, 2012 \[[@B21]\]            Finland       Case--control                      People invited to heath check up in 2004                        45             52            766              EIA                      NCEP ATPIII                        With MS: 216 ± 165^d^ Without MS: 151 ± 112^d^                               With MS: 94 ± 75^d^ Without MS: 61 ± 48^d^                    28
            Leiva, 2013 \[[@B19]\]               Chile       Cross-sectional       Research program of Risk Factors for Cardiovascular Disease of Talca          31             57            155              EIA                      NCEP ATPIII                      With MS: 72 (47--112)^h^ Without MS: 55 (36--96)^h^                        With MS: 54 (34--85)^h^ Without MS: 27 (13--60)^h^                30
            Chang, 2013 \[[@B22]\]              Taiwan       Cross-sectional     Third national nutritional and health survey in Taiwan (NAHSIT 2005-2008)       43             55           2,654             EIA                 NCEP ATPIII modified                                     229 ± 349^d^                                                               119 ± 180^d^                                   27
             Li, 2013 \[[@B31]\]                 China       Cross-sectional                         China Health and Nutrition Survey                           47             51           8,441             RIA                 NCEP ATPIII modified                                  Q1:52^a^ Q4:423^a^                                                       Q1:12.9^a^ Q4:142.7^a^                              30

EIA, Electrochemiluminescence immunoassay; NIA, Nephelometric immunoassay; NR, not reported; RIA, immunoradiometric assay; TIA, immunoturbidimetric assay. \*Quality score of STROBE Statement.

^a^Median of quartile; ^b^Geometric mean (95% CI); ^c^Geometric mean ± SD; ^d^Mean ± SD; ^e^Mean of quartile (minimum-maximum); ^f^Geometric mean ± SE; ^g^Median (range); ^h^Geometric mean (range).

SD: standard deviation; SE: standard error; CI: confidence interval; MS: metabolic syndrome; Q1: quartile 1; Q4: quartile 4: T1: tertile 1; T3: tertile 3.

The STROBE quality score of studies included 7 had 30 points or more while 5 studies had \<30 points.

The metabolic syndrome was defined according with the criteria by the National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP ATP III) \[[@B33]\] in all studies except one defined by International Diabetes Federation Task Force on Epidemiology and Prevention \[[@B26]\].

Meta-analysis of serum ferritin levels and metabolic syndrome
-------------------------------------------------------------

Data from a total of 56,035 participants were analyzed. The pooled OR when comparing the highest to the lowest category of ferritin levels and metabolic syndrome was 1.73 (95% CI: 1.54, 1.95); heterogeneity: *P* \< 0.001; *I*^2^ = 75,4% (Figure [2](#F2){ref-type="fig"}). The pooled OR for men was 1.69 (95% CI: 1.29, 2.21); heterogeneity: *P* \< 0.001; *I*^2^ = 87,7%; for women it was 1.65 (95% CI: 1.41, 1.94); heterogeneity: *P* = 0.002; *I*^2^ = 63.7% and for studies that included both genders it was 1.87 (95% CI: 1.56, 2.23); heterogeneity: *P* = 0.073; *I*^2^ = 53.2%.

![**Meta-analysis of the association of ferritin levels with metabolic syndrome in observational studies.** Studies are divided by gender (men, women and both genders). Odds ratios correspond to comparisons of extreme categories of exposure within each study. The area of each square is proportional to the inverse of the variance of the log odds ratio. Horizontal lines represent 95% CI. Diamonds represent pooled estimates from inverse-variance weighted random-effects models. NR, not reported.](1471-2458-14-483-2){#F2}

Meta-regression and subgroup analysis showed that adjusting by CRP and quality of studies significantly influenced the pooled estimates (*P* = 0.044 and *P* = 0.038 respectively) (Table [2](#T2){ref-type="table"}). An stronger association between ferritin levels and metabolic syndrome was detected in studies adjusted by CRP \[OR = 1.92 (95% CI: 1.61, 2.30; *I*^2^ = 78%)\] compared to studies that did not adjust by CRP \[OR = 1.52 (95% CI: 1.36, 1.69; *I*^2^ = 41%)\]. Moreover, studies with high quality (≥30 points) showed a stronger association between serum ferritin levels and metabolic syndrome compared to studies with medium-poor quality (\<30 points) (OR = 1.87 vs OR = 1.43).

###### 

Stratified odds ratio for metabolic syndrome

  **Subgroup**                      **Number of studies**   **Odds ratio (95% CI)**   ***I***^**2**^   ***P*-value**
  -------------------------------- ----------------------- ------------------------- ---------------- ---------------
  **Study design**                                                                                            
  Prospective cohort                          2                1.59 (1.38, 1.82)            0%                
  Cross-sectional                            12                1.78 (1.51, 2.09)           81%                
  Case--control study                         1                1.65( 1.43, 1.91)            0%             0.551
  **Measure of association**                                                                                  
  Odds Ratio                                 13                1.62 (1.47, 1.79)           47%                
  Hazard Ratio                                2                1.61 (1.49, 1.75)           37%             0.520
  **Geographic area**                                                                                         
  Asian                                       9                1.67 (1.38, 2.02)           84%                
  Europe                                      4                1.66 (1.50, 1.83)           14%                
  American                                    2                2.41 (1.77, 3.27)           11%             0.239
  **Adjusted for CRP**                                                                                        
  Yes                                         9                1.92 (1.61, 2.30)           78%                
  No                                          6                1.52 (1.36, 1.69)           41%             0.044
  **Quality of SCORE statement**                                                                              
  \<30 points                                 4                1.43 (1.27, 1.61)            0%                
  ≥30 points                                 11                1.87 (1.62, 2.17)           79%             0.038
  **Ferritin assay**                                                                                          
  RIA                                         5                1.93 (1.49, 2.51)           85%                
  TIA                                         2                1.53 (1.08, 2.16)           64%                
  Others                                      6                1.56 (1.42, 1.70)           17%             0.091
  **Study size, population**                                                                                  
  \<300                                       4               1.76 (1.512, 2.06)           57%                
  ≥300                                       11                1.70 (1.46, 1.98)           78%             0.152

CRP, C-reactive protein; RIA, immunoradiometric assay; TIA, immunoturbidimetric assay.

Other sources of heterogeneity investigated, such as study design (*P* = 0.551), measure of association (*P* = 0.520), geographic area (*P* = 0.239), ferritin assay technique (*P* = 0.091), study size (*P* = 0.152), did not influence pooled estimates (Table [2](#T2){ref-type="table"}).

In sensitivity analyses, the exclusion of individual studies did not modify the estimates substantially and the pooled odds ratio ranged from 1.64 to 1.76.

Discussion
==========

The present study is the first meta-analysis summarizing the independent positive association between ferritin levels and the metabolic syndrome. The highest category of ferritin levels was independently associated with a 1.73 higher presence of metabolic syndrome when compared to the lowest category. This association was stronger when adjusted for an inflammatory biomarker such as CRP levels. The initial results of the meta-analysis were consistent when tested for sensitivity analyses.

The positive independent association between serum ferritin levels and presence of metabolic syndrome is biologically plausible. Iron is an essential trace element for the human body, involved in cellular processes and a key component of various enzymes. It can also be toxic due to oxidative stress generation by the Fenton reaction, causing organic biomolecular oxidation \[[@B34]\]. This process is at the basis of pathologies like diabetes mellitus, neoplasia and degenerative brain disorders \[[@B34],[@B35]\].

Moreover, the use of iron chelation therapy to reduce serum ferritin levels was associated with improved serum glucose or HDL levels \[[@B36]\]. Houschyar et al. studied the effects of phlebotomy and the control of body iron in patients with metabolic syndrome in a randomized, controlled, single-blind clinical trial. The authors concluded that in patients with metabolic syndrome, phlebotomy with a moderate reduction of body iron stores lowered blood pressure and resulted in improvements of markers of cardiovascular risk and glycemic control \[[@B37]\].

The strengths of our study are that the analysis included a large number of subjects (56,053 participants) and thirteen \[[@B11]-[@B22],[@B31],[@B32]\] out of the fifteen studies used the NCEP ATP III criteria to diagnose the metabolic syndrome, which is important to reduce possible bias in the results of the individual studies.

Although the odds ratio may overestimate the risk if interpreted as a relative risk, substantial differences between the odds ratio and the relative risk are seen only when the effect size are large and the initial risk is high \[[@B38]\]. In our study, the meta-regression and subgroup analysis did not show difference between odds ratio and hazard ratio (p meta-regression = 0.520) (1.61 vs 1.62), for this reason we combined odds ratio and hazards ratio in pooling analysis.

Another limitation of this meta-analysis is related to the high heterogeneity. However, this elevated heterogeneity was not explained by the study design, type of measure of association, geographic area, ferritin assay technique or study size. Only the use or not of the inflammatory biomarker CRP as control variable and the quality of the studies (≥30 points or \< 30 points) were identified as sources of heterogeneity by the subgroup analyses and meta-regression. A possible explanation is that serum ferritin level is an acute-phase reactant and, in the presence of acute or chronic inflammation, may raise several-fold above baseline levels \[[@B39],[@B40]\]. By adjusting by CRP, a proinflammatory biomarker, we controlled for the confounder effect of inflammation, and thus, the association between ferritin levels, as a marker of excessive body iron stores, and the metabolic syndrome was strengthened. We therefore believe it is advisable to use a biomarker of inflammation in the studies investigating the relationship between ferritin and the metabolic syndrome and to ensure that the studies are of high methodological quality.

Another important limitation of this meta-analysis is that cross sectional studies cannot be used to infer a causal role of serum ferritin on the risk of developing metabolic syndrome. Indeed, the mechanisms underlying the relationship between increased ferritin and the metabolic syndrome still need to be clarified. However, we can consider that the results from the twelve cross sectional studies \[[@B11]-[@B20],[@B22],[@B31]\], one case--control study \[[@B21]\] are supported by the results of two prospective studies \[[@B26],[@B32]\], conducted in France (944 participants) and in Korea (13,084 participants) \[[@B26],[@B32]\], which established that high levels of serum ferritin preceded the development of metabolic syndrome.

Supporting the biologically plausible pathogenic role of elevated iron, there are other longitudinal studies that noted that high serum ferritin could be a risk factor to develop chronic diseases, especially those related to the metabolic syndrome. Recently, in a Korean cohort on 17,812 healthy men, elevated serum ferritin levels were identified as a predictive factor for obesity \[[@B41]\]. Furthermore, the evidence on a relationship between excess iron and cardiovascular disease has steadily increased over the years \[[@B8],[@B42],[@B43]\]. Moreover, several prospective studies have identified excess iron as a risk factor for T2DM. In the Nurses\' Health Study cohort the subjects in the highest quintile had a 2.5 fold higher diabetes-risk than those in the lowest quintile \[[@B40]\]. Similarly, results from the cohort of the European Prospective Investigation into Cancer and Nutrition study (EPIC) also supported the hypothesis that higher iron stores below the level of haemochromatosis are associated with risk of type 2 diabetes \[[@B44]\]. In addition, two recent systematic review and meta-analysis of published prospective studies have confirmed the same relationship \[[@B3],[@B4]\]. Nevertheless, we want to emphasize that our meta-analysis focused on the metabolic syndrome as the primary outcome and that articles on patients with type 2 diabetes mellitus were excluded.

Although several authors have postulated that levels of iron in the upper limit of the normal range are associated with pathological processes \[[@B45],[@B46]\], at present we do not know the cut-off value of serum ferritin concentration that defines the "high level" and that can be considered as a risk factor of metabolic syndrome. The World Health Organization (WHO) has identified levels of ferritin to define iron overload (\>200 μg/L for men and \>150 μg/L for women) \[[@B40]-[@B47]\]. In the studies included in our meta-analysis, we observed that cut-offs of ferritin (≥147 μg/L) in the highest quartile or quintile \[[@B11],[@B18],[@B20],[@B26]\] and the geometric mean of the highest quartile were similar o even lower to the levels used to define iron overload in men. In women the values of ferritin that were associated with metabolic syndrome were 89 μg/L in premenopausal and 212 μg/L in postmenopausal women \[[@B11]\]. These are lower than the values of iron overload defined by the WHO in premenopausal women \[[@B11],[@B18],[@B20]\].

Some studies have observed that premenopausal women have a lower prevalence of hyperferritinemia compared with postmenopausal women, because of iron losses by menstruation and increased consumption during pregnancy \[[@B13]\].

The results of our meta-analysis suggest that the metabolic syndrome could already develop in men and in premenopausal women at ferritin levels that are lower than the WHO cut-offs for iron overload.

High serum ferritin concentrations could potentially be used as a screening biomarker to detect those at risk of developing the metabolic syndrome and those in the early stages of the disease that can still be reversed by targeted preventive measures. For this purpose, data from other countries and races will also be necessary to strengthen our understanding of this relationship and to establish the correct cut-off values of ferritin for each population group.

Conclusions
===========

In summary, the results of the present meta-analysis indicate that serum high levels of ferritin are independently and positively associated with the metabolic syndrome. Additional prospective studies are needed to confirm if high serum ferritin is a valid biomarker of metabolic syndrome risk, to evaluate the influence of inflammation and to identify pathological cut-off values.
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